Bristol-Myers Squibb Company (NYSE:BMY) is one of the 25 stocks Jim Cramer recently shared insights on. While discussing drug ...

BMY’s robust launch portfolio, resilient free cash flow, and above-consensus growth outlook position it for outsized returns ...

Bristol Myers Squibb to cut 68 jobs in Lawrenceville as part of a broader restructuring effort aiming to slash $2B in costs ...

The healthcare sector, represented by the Health Care Select Sector SPDR Fund (NYSEARCA:XLV), underperformed the broader ...

Cigna claims Bristol Myers’ Celgene unit filed sham lawsuits it knew it was unlikely to win in an effort to protect its ...

Bristol Myers Squibb (BMY) closed the most recent trading day at $47.51, moving +2.64% from the previous trading session. The stock's performance was ahead of the S&P 500's daily loss of 0.11%. On the ...

The mood is better than the numbers suggest. The doom-loop panic of March and April is behind us, even though the XBI has ...

Two months after Bristol Myers Squibb fended off a lawsuit which accused the drugmaker of using illegal tactics to protect ...

Bristol-Myers Squibb’s first quarter results reflected a blend of strong execution in its newer growth portfolio and ongoing ...

On Wednesday, Biokin reported (PDF) positive topline results from a phase 3 trial of the ADC. The study enrolled patients ...